CL2013002870A1 - Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer. - Google Patents
Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer.Info
- Publication number
- CL2013002870A1 CL2013002870A1 CL2013002870A CL2013002870A CL2013002870A1 CL 2013002870 A1 CL2013002870 A1 CL 2013002870A1 CL 2013002870 A CL2013002870 A CL 2013002870A CL 2013002870 A CL2013002870 A CL 2013002870A CL 2013002870 A1 CL2013002870 A1 CL 2013002870A1
- Authority
- CL
- Chile
- Prior art keywords
- salt
- treatment
- cancer
- dihydroimidazo
- quinazolin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161111A EP2508525A1 (en) | 2011-04-05 | 2011-04-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002870A1 true CL2013002870A1 (es) | 2014-06-20 |
Family
ID=43984137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002870A CL2013002870A1 (es) | 2011-04-05 | 2013-10-04 | Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer. |
Country Status (42)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| WO2014198817A1 (en) | 2013-06-14 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Anti-tweakr antibodies and uses thereof |
| CN103694319B (zh) * | 2013-12-20 | 2018-02-27 | 深圳翰宇药业股份有限公司 | 一种布舍瑞林的纯化方法 |
| EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| JP2018512403A (ja) * | 2015-03-09 | 2018-05-17 | バイエル ファーマ アクチエンゲゼルシャフト | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 |
| CA2978830A1 (en) * | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| HUE048111T2 (hu) | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| EP3411497A1 (en) | 2016-02-01 | 2018-12-12 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| CA3012951A1 (en) | 2016-02-01 | 2017-08-10 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| MA45280B1 (fr) | 2016-03-02 | 2021-08-31 | Eisai R&D Man Co Ltd | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| CA3045041A1 (en) | 2016-12-14 | 2018-06-21 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| WO2018153980A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| CN111278430A (zh) * | 2017-09-08 | 2020-06-12 | 拜耳制药股份公司 | 库潘尼西制剂 |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| EP3866805A1 (en) * | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| WO2020079079A1 (en) | 2018-10-17 | 2020-04-23 | Sandoz Ag | Co-crystals comprising levothyroxine and a dicarboxylic acid |
| AU2019416623B2 (en) * | 2018-12-27 | 2022-12-08 | Holosmedic | Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity |
| WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
| WO2025053315A1 (ko) * | 2023-09-08 | 2025-03-13 | 파로스젠 주식회사 | 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH588505A5 (enExample) | 1972-06-08 | 1977-06-15 | Research Corp | |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB0021865D0 (en) | 2000-09-06 | 2000-10-18 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU2003293310B2 (en) | 2002-09-30 | 2010-04-01 | Bayer Intellectual Property Gmbh | Fused azole-pyrimidine derivatives |
| JP4323793B2 (ja) | 2002-12-16 | 2009-09-02 | キヤノン株式会社 | ズームレンズ及びそれを有する光学機器 |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JP5620275B2 (ja) * | 2008-01-14 | 2014-11-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類 |
| EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| PE20130191A1 (es) | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| JP6499657B2 (ja) | 2013-12-03 | 2019-04-10 | バイエル ファーマ アクチエンゲゼルシャフト | Ｐｉ３ｋ阻害剤の組み合わせ |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| JP2018512403A (ja) * | 2015-03-09 | 2018-05-17 | バイエル ファーマ アクチエンゲゼルシャフト | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 |
-
2011
- 2011-04-05 EP EP11161111A patent/EP2508525A1/en not_active Withdrawn
-
2012
- 2012-03-27 JO JO201264A patent/JO2958B1/en active
- 2012-03-28 UY UY0001033985A patent/UY33985A/es not_active Application Discontinuation
- 2012-03-28 AR ARP120101036A patent/AR085718A1/es not_active Application Discontinuation
- 2012-03-29 DK DK12712104.4T patent/DK2694508T3/en active
- 2012-03-29 ME MEP-2015-16A patent/ME02021B/me unknown
- 2012-03-29 ES ES12712104.4T patent/ES2529653T3/es active Active
- 2012-03-29 BR BR112013025549A patent/BR112013025549A2/pt not_active Application Discontinuation
- 2012-03-29 UA UAA201312858A patent/UA111604C2/uk unknown
- 2012-03-29 CU CUP2013000133A patent/CU24208B1/es active IP Right Grant
- 2012-03-29 CN CN201280027509.4A patent/CN103649091B/zh not_active Expired - Fee Related
- 2012-03-29 AU AU2012238891A patent/AU2012238891B2/en not_active Ceased
- 2012-03-29 JP JP2014503079A patent/JP5763834B2/ja not_active Expired - Fee Related
- 2012-03-29 RS RS20150077A patent/RS53811B1/sr unknown
- 2012-03-29 PL PL12712104T patent/PL2694508T3/pl unknown
- 2012-03-29 SG SG2013071501A patent/SG193595A1/en unknown
- 2012-03-29 SI SI201230138T patent/SI2694508T1/sl unknown
- 2012-03-29 US US14/009,599 patent/US10383876B2/en active Active
- 2012-03-29 EA EA201391470A patent/EA023646B1/ru not_active IP Right Cessation
- 2012-03-29 MX MX2013011583A patent/MX336057B/es unknown
- 2012-03-29 PE PE2013002186A patent/PE20141038A1/es active IP Right Grant
- 2012-03-29 CA CA2832123A patent/CA2832123C/en active Active
- 2012-03-29 EP EP12712104.4A patent/EP2694508B1/en active Active
- 2012-03-29 KR KR1020137028852A patent/KR101937501B1/ko not_active Expired - Fee Related
- 2012-03-29 PH PH1/2013/502065A patent/PH12013502065A1/en unknown
- 2012-03-29 PT PT127121044T patent/PT2694508E/pt unknown
- 2012-03-29 MA MA36288A patent/MA35014B1/fr unknown
- 2012-03-29 WO PCT/EP2012/055600 patent/WO2012136553A1/en not_active Ceased
- 2012-03-29 HR HRP20150138TT patent/HRP20150138T1/hr unknown
- 2012-03-29 MY MYPI2013701860A patent/MY169452A/en unknown
- 2012-03-29 AP AP2013007219A patent/AP3709A/en active
- 2012-03-30 TW TW105122778A patent/TWI592158B/zh not_active IP Right Cessation
- 2012-03-30 TW TW101111580A patent/TWI549954B/zh not_active IP Right Cessation
-
2013
- 2013-09-20 ZA ZA2013/07105A patent/ZA201307105B/en unknown
- 2013-09-29 IL IL228561A patent/IL228561A/en active IP Right Grant
- 2013-10-03 TN TNP2013000401A patent/TN2013000401A1/fr unknown
- 2013-10-04 CO CO13236625A patent/CO6781534A2/es not_active Application Discontinuation
- 2013-10-04 CL CL2013002870A patent/CL2013002870A1/es unknown
- 2013-10-04 DO DO2013000223A patent/DOP2013000223A/es unknown
- 2013-10-04 CR CR20130511A patent/CR20130511A/es unknown
- 2013-10-04 GT GT201300234A patent/GT201300234A/es unknown
- 2013-11-04 EC ECSP13013006 patent/ECSP13013006A/es unknown
-
2015
- 2015-02-12 SM SM201500037T patent/SMT201500037B/xx unknown
- 2015-02-19 CY CY20151100174T patent/CY1116231T1/el unknown
- 2015-04-28 JP JP2015091455A patent/JP5826961B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-07 US US14/990,350 patent/US9636344B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085718A1 (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida | |
| CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. | |
| PH12015502797B1 (en) | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MX2015013945A (es) | Derivados de urea utiles como inhibidores de quinasa. | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2015015845A (es) | Derivados de pirimidin-4-il)-oxi)-1h-indol-1-carboxamida y uso de los mismos. | |
| CU20100004A7 (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k |